•
Sep 30, 2020

Bio-Techne Q1 2021 Earnings Report

Bio-Techne's Q1 2021 financial results were released, showing revenue growth and increased profitability.

Key Takeaways

Bio-Techne reported a strong first quarter for fiscal year 2021, with organic revenue growth of 10% and adjusted EPS increasing by 35%. The company benefited from the reopening of customer sites and demand for its life science tools and diagnostic reagents.

Organic revenue increased by 10% to $204.2 million.

GAAP EPS was $0.83, while adjusted EPS was $1.43, a 35% increase year-over-year.

Diagnostics and Genomics segment delivered 17% organic growth.

Adjusted operating margin increased to 38.2%.

Total Revenue
$204M
Previous year: $183M
+11.4%
EPS
$0.36
Previous year: $0.27
+33.3%
Organic Sales Growth
10%
Gross Profit
$138M
Previous year: $118M
+16.3%
Cash and Equivalents
$169M
Previous year: $99.9M
+69.6%
Free Cash Flow
$55.1M
Previous year: $30M
+83.5%
Total Assets
$2.05B
Previous year: $1.93B
+6.7%

Bio-Techne

Bio-Techne

Bio-Techne Revenue by Segment

Forward Guidance

The company anticipates a positive long-term outlook for sales growth resulting from expected future funding increases within life-science research in response to the current pandemic.

Revenue & Expenses

Visualization of income flow from segment revenue to net income